Cochrane Summaries

Trusted evidence. Informed decisions. Better health.
Language:
English

Rivastigmine appears to moderately improve cognition and to a lesser extent activities of daily living in patients with PDD

Maidment I, Fox C, Boustani M
Published Online: 
16 July 2008

Dementia is frequently associated with Parkinson's Disease. While a number of neurotransmitters appear to be involved, loss of cholinergic functioning is particularly associated with Parkinson's Disease Dementia (PDD) suggesting a potential utility for cholinesterase inhibitors. Rivastigmine appears to moderately improve cognition and to a lesser extent activities of daily living in patients with PDD. There was a clinically meaningful benefit in 15% of patients. Efficacy in other domains requires confirmation. Tolerability in particular nausea, vomiting and tremor appear problematic.

This record should be cited as: 
Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004747. DOI: 10.1002/14651858.CD004747.pub2
Assessed as up to date: 
6 May 2008